Introduction {#sec1-1}
============

Hematopoietic stem cell transplant (HSCT) has recently emerged as a cure for previously "incurable" diseases. Its first application was in 1957 for a leukemia patient who received a transfer of stem cell from the healthy twin conferring a "cure" state which was previously not achieved with traditional chemotherapy. (Pidala et al., 2011; Henig and Zuckerman, 2014) Since the breakthrough with the experiment, the horizon of hematopoietic stem cell transplant has expanded to involve other sources of stem cells including cells from unrelated donors or cord blood stem cell stored in the international banks (Kondo et al., 2003; Stacey and Hunt, 2006; Lin et al., 2013) Even now, newer sources such as mesenchymal tissue or other differentiated cellular lineages (Sordi and Piemonti, 2011; Keating, 2012) are also being investigated for cure of various congenital, autoimmune and malignant diseases. It is proper to say that, the potential for application is limitless (Kondo et al., 2003; Stacey and Hunt, 2006; Girlovanu et al., 2015).

However, on the same expanding frontier, the long-term side effects of transplant and accommodating treatment modalities are still understudied. It is estimated that over 8,000 HSCT was performed in the US in 2017 and the number continues to grow for both autologous as well as allogeneic HSCT (D'Souza et al., 2017). From such an astounding number; at the aftermath of the battle, what consequences are the survivors encountering? (Hilgendorf et al., 2015) Previous studies had mentioned the possibilities of developing hypertension, dyslipidemia as well as endocrinologic abnormalities with various risk factors (Baker et al., 2007; Hoffmeister et al., 2010; Wei et al., 2016; Bielorai et al., 2017). Not to mention known co-morbidities from the treatment itself such as graft versus host disease (GVHD) (Socie and Ritz, 2014; Arora et al., 2016) or infectious complications (Nakano et al., 2014; Kumar et al., 2015) which are well known to associate with the immunocompromised state rendered by the treatments (Michael et al., 2013).

Part of the treatment with HSCT is the conditioning regimen which includes a combination of chemotherapy and radiation therapy. Most adverse effects of various chemotherapy regimens including short and long-term complications have been well studied. However, for application of total body irradiation (TBI), the long-term side effect is still to be discovered. The fact that TBI can render the hematopoietic stem cell powerless signifies that other mechanisms are playing a role in other organs and metabolic pathways as well.

We aimed to explore the potential long-term outcome after HSCT and TBI on the development of diabetes mellitus (DM) or impaired glucose metabolism (IGM).

Materials and Methods {#sec1-2}
=====================

Patients and method {#sec2-1}
-------------------

We searched for titles of articles in the MEDLINE (PubMed), EMBASE, and Cochrane library. We performed a search in August 2018 and did not restrict publication dates. The following main search terms were used: hematopoietic stem cell transplant, total/whole body irradiation and diabetes mellitus/impaired glucose metabolism. The full search strategy is detailed in Item S1 in the Supplementary Material.

All published nonrandomized trials that evaluated the association between TBI in the setting of HSCT and DM or IGM were included. Observational studies−prospective cohort, retrospective cohort and cross-sectional studies−were included. Review articles, case reports, letters, commentaries, abstracts, unpublished studies and studies in languages other than English were not included.

Patient's age was not part of the exclusion criteria as both adult and pediatric patients were included in our analysis. Studies that did not assess the direct association of DM/IGM with TBI or did not have eligible study population were excluded (Chemaitilly et al., 2009; Majhail et al., 2009; Baker et al., 2010; Frisk et al., 2011; Sohn et al., 2011; Bizzarri et al., 2015; Davis et al., 2015; Wei et al., 2015; Wilhelmsson et al., 2015; Wei et al., 2016; Bielorai et al., 2017; Friedman et al., 2017).

The primary outcome was the diagnosis of DM/IGM, which was measured by standardized blood tests recommended by American Diabetes Association (ADA) (American Diabetes, 2018) or self-report questionnaire given to patients or their primary care physicians. We compared the risks of DM/IGM diagnosis between patients who did and did not receive TBI as part of the conditioning regimen for HSCT.

Data extraction and quality assessment {#sec2-2}
--------------------------------------

Two investigators independently extracted the following data: Authors, publication year, country of origin, study design, baseline patient's characteristics, interventions, and outcomes. Any conflicting opinions on data extraction were resolved by consensus of the investigators.

The Newcastle − Ottawa Quality Assessment Scale (NOS) was used to assess the quality of the nonrandomized studies based on the selection of the study groups, comparability of study groups, and ascertainment of exposure/outcome. Studies with total scores of \>6 and \<4 were considered to be of high and low quality, respectively. We excluded any studies that the meta-analysis indicated poor quality. There were no randomized or blinded control trials due to the obvious nature of the intervention.

Statistical methods {#sec2-3}
-------------------

The primary outcome of the study is the pooled mean difference (MD) of the risk of development of DM/IGM between patients who received TBI compared with patients who did not receive TBI. We used a random-effects model as included studies are observational study. We conducted sensitivity analysis and subgroup analysis to explore heterogeneity of the included studies (Higgins et al., 2003). We used Funnel plot (as detailed in Item S2 in the Supplementary Material) and Egger's test to assess for publication bias. All analyses were performed using Stata 13 software.

Results {#sec1-3}
=======

Description of included studies {#sec2-4}
-------------------------------

The initial search yielded 1,388 articles; 1,365 were excluded from title and abstract review as they were obviously not pertaining to our study, did not involve TBI as part of the conditioning regimen, did not evaluate association between TBI and DM/IGM, were not conducted in patients receiving HSCT, conducted in animal models, or were published in languages other than English. A total of 23 articles underwent full-length review. 12 of them were excluded because they did not have a TBI control group or did not have an eligible study population. Finally, we included 11 studies: Five retrospective cohort studies, three prospective cohort studies and two cross-sectional studies. They included 13,191 patients with indications for HSCT, 2,695 who had undergone TBI and 10,266 who had not (controls). Figure S3 In the supplementary material outlined our search methodology and selection process. [Table 1](#T1){ref-type="table"} described the characteristics of the extracted studies. The total sample size range was 22-8,599 patients. The mean age range was 7-44 years. The follow-up duration ranged from 2-30 years. DM/IGM was diagnosed by blood sample per ADA (American Diabetes, 2018) guideline, from self-report or contact with patients' primary care physicians.

###### 

Study Characteristics

  study Name    country     year             \"study design\"   \"Average follow up time (year)\"   \"Population (case/control) \"   \"% female\"   \" Average age (A/P)2\"   \"HSCT indication Ma/Co/Me/ MaHe\"   \"HSCT Type Allo/Auto\"   \"TBL/no TBL\"   DM diagnosis
  ------------- ----------- ---------------- ------------------ ----------------------------------- -------------------------------- -------------- ------------------------- ------------------------------------ ------------------------- ---------------- ---------------------------------------
  Armenian      USA         \"1995- 2004\"   RC                 5.9                                 1885/5655                        57.7           44.4 at HSCT(A)           Ma                                   806/1157                  994/891          \"Blood Test7 or on DM treatment\"
  Baker         USA         \"1974- 1998\"   RC                 8.6                                 1089/792                         44.9           30.8 at HSCT(A)           Ma/Me                                590/499                   804/285          Patient survey
  Hirabayashi   Japan       \"1996- 2010\"   RC                 14.1                                22 cases                         68.2           7.4 at HSCT(P)            MaHe                                 All Allo                  21/1             Blood Test
  Hoffmeister   USA         \"1969- 1999\"   RC                 11                                  748 cases                        40             9.4 at HSCT(P)            MaHe                                 642/106                   528/22           \"Patient and PcP Survey\"
  Meacham       USA         \"1970- 1986\"   XS                 N/A1                                8599/2936                        48.5           31.5 at study(P)          Ma                                   N/A                       112/8487         Patient survey
  Nakagawa      Japan       \"1983- 2013\"   PC                 9.5                                 22 cases                         36.4           7.5 at HSCT(P)            Ma                                   18/4                      10/12            Blood Test7
  Neville       Australia   \"1971- 2000\"   PC                 N/A1                                248 cases                        42.3           18 at study(P)            Ma/co                                N/A                       18/21            \"Blood Test7 , OGTT9\"
  Oudin2010     France      \"1980- 2008\"   PC                 14.5                                184                              48.4           21.2 at study(P)          MaHe                                 39/21                     43/143           \"Blood Test7 or on DM treatment\"
  Oudin2015     France      \"2007- 2012\"   PC                 14.5                                170 cases                        45.9           24.8 at study(P)          MaHe                                 124/46                    124/46           \"Blood Test7 or on DM treatment\"
  shalitin      Isreal      \"1988- 2012\"   RC                 8.5                                 178 cases                        37.6           15.5 at study(P)          Ma/co                                116/62                    23/155           Blood Test7
  Taskinen      Finland     \"1980- 1995\"   XS                 5.5                                 23/36                            39.1           20.4 at study(P)          MaHe/Co                              All Allo                  18/5             \"Blood Test7 OGTT9 or HOMA model10\"

Acronym: Retrospective cohort study; RC, Prospective; cohort study; PC,Cross sectional study;XS; 1Follow up time is not applicable in cross; sectional study; 2Average age: Adult;A, Pediatric;P; 3Hematopoietic stem cell transplant ; HSCT; indication:Malignant condition: Ma, Congential; disease;Co,Metabolic disease;Me,Malignant; hematologic condition ; MaHe; 4HSCT type:Allogenic;Allo,Autologous;Auto 5Total body irradiation ; TBI 6DM;Diabetes Mellitus 7Blood Test criteria according to ADA guidekine (American Diabetes , 2018); 8Questionnaire to patient,s primerary care;doctor ; asking for DIAGNOSIS AND BLOOD TEST RESULT;9ogtt (oral glucose tolerance test)(American Diabetes,2018);10HOMA model:insulin resistance(katuki et al., 2001)

Meta-analysis results {#sec2-5}
---------------------

There were 11 studies included in this meta-analysis. Using a random-effects model, the pooled MD of diagnosis of DM/IGM was found to be significantly higher in the TBI group than in the control group (MD = 5.42, 95% Confidence Interval (CI) 2.51-11.71). The heterogeneity among studies (I^2^) was 92.4%. We found publication bias from Funnel plot which was not statistically significant from Egger's test (P = 0.466). This is likely due to less likelihood of negative studies being selected for publication.

See details for meta-analysis in S4 in Supplementary Material {#sec2-6}
-------------------------------------------------------------

Subgroup analysis {#sec2-7}
-----------------

We conducted a subgroup analysis to assess the effect of age, study design and indication for HSCT on the primary outcome.

First, for age group, we categorized the studies to include only pediatric population and the other for adult patients. Pooled MD among adult group (Baker et al., 2007; Armenian et al., 2012) was 2.09, 95% CI 0.95-4.61, I^2^=71.7% while for the pediatric group (Taskinen et al., 2000; Hoffmeister et al., 2004; Neville et al., 2006; Oudin et al., 2011; Michael et al., 2013; Hirabayashi et al., 2014; Oudin et al., 2015; Nakagawa et al., 2018; Shalitin et al., 2018), the pooled MD was 8.43, 95% CI 5.51-12.91, I^2^=44.4%.

![Funnel Plot](APJCP-20-885-g001){#F1}
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In addition, for the study designs, we categorized the studies into prospective, cross-sectional and retrospective studies and found the following pooled MD: 3.21, 95% CI 1.53-6.73, I^2^=71.3% for retrospective studies (Hoffmeister et al., 2004; Baker et al., 2007; Armenian et al., 2012; Hirabayashi et al., 2014; Shalitin et al., 2018) while for prospective study the pool MD was 12.75, 8.77-18.53, I^2^=16.3%, and 6.76, 95% CI 3.32-13.74, I^2^=0% for cross-sectional studies (Taskinen et al., 2000; Meacham et al., 2010).

Lastly, if we divide the studies with regards to the indication of HSCT. One group evaluates only patients with malignant hematologic (MaHe) condition and the other group for all other conditions. The MaHe group (Hoffmeister et al., 2004; Oudin et al., 2011; Hirabayashi et al., 2014; Oudin et al., 2015) has the pooled MD of 4.98, 95% CI1.85-13.42, I^2^=0% and the other studies with pooled MD of 5.55, 95% CI 2.02-15.25, I^2^=95.4% (Taskinen et al., 2000; Neville et al., 2006; Baker et al., 2007; Meacham et al., 2010; Armenian et al., 2012; Nakagawa et al., 2018; Shalitin et al., 2018).

According to this regression meta-analysis, differences in age group and indications for HSCT potentially had effect modification to the association between TBI and the diagnosis of DM/IGM, which could be used to identify high risk population. In addition, we recognized that cross-sectional study design has limitations to accurately diagnose DM/IGM after patients received TBI as the diagnosis is based on a single timeframe rather than a prolonged period of follow-up time in cohort studies. The association remained statistically significant after exclusion of two cross-sectional studies. Therefore, we concluded that a diagnosis of DM/IGM is markedly increased in patients who received TBI as part of the conditioning regimen compared to other conditioning regimens in the setting of HSCT. This observed association was stronger among prospective studies, pediatric population, non-US based studies and studies done exclusively for a malignant hematologic condition.

Discussion {#sec1-4}
==========

This meta-analysis investigated the effect of TBI on the development of DM/IGM in patients indicated for HSCT. Our main findings suggested that TBI was significantly associated with an increased risk of the development of DM/IGM compared to those who did not undergo TBI as part of the conditioning regimen for HSCT.

There have been many theories as to why TBI can cause DM/IGM (Chemaitilly et al., 2009). Starting from the fact that TBI; as other types of radiation do is causing inflammation. Most radiation is site-specific, thus limiting the extent of the inflammation to a targeted region, however, as the name suggested, TBI; total body irradiation can cause systemic inflammation and interfere with molecular signaling, cascade pathways and more significantly can induce hormonal disturbances. The central result of all the inflammation caused by the TBI is insulin resistance. This is theorized to be from growth hormone deficiency (Martin and Jeanrenaud, 1985; Bakker et al., 2007; Nakagawa et al., 2018) or abnormal adipose tissue redistribution. (Rajendran et al., 2013; Bizzarri et al., 2015) Other more, site-specific issues are from reduced pancreatic beta-cell reserve and an overall decrease in pancreatic volume directly induced by the TBI (Wei et al., 2015; Arora et al., 2016). All of these theories could well explain how TBI can be associated with the development of DM/IGM.

On the contrary, there has long been speculation that various treatments modalities associated with HSCT itself can increase the risk of developing DM/IGM. (Griffith et al., 2010) including, but not limited to chemotherapy, prolonged use of corticosteroid and various immunosuppressants (Vantyghem et al., 2014; Abou-Mourad et al., 2010; Mostoufi-Moab et al., 2016), which are well known to be associated with truncal obesity and potentially DM/IGM when used for prolonged period of time as well as physical inactivity resulting from prolonging hospitalization (Inoue et al., 2010; Al Tunaiji et al., 2014).

In addition, we found potential publication bias visualized from the Funnel plot, although it did not meet statistical significance in Egger's test. We believed that they were fewer published negative studies, which contributed to publication bias. Although it is generally recognized that small negative studies were difficult to get published in high quality scientific journals, we used general broad search terms as described in supplemental material S1 to include small negative studies as much as we could to minimize publication bias.

There are some limitations to this study. First, only 11 studies met our inclusion criteria, most of which were conducted in the USA, possibly limiting the external validity of this meta-analysis. Secondly, patients of varying age and pre-transplant co-morbidity were included in the study which could be confounding the test result. Thirdly, some studies included patients with known endocrinologic disorders such as hypothyroidism, hypogonadism and growth hormone deficiency which could influence the development of DM/IGM. And lastly, we recognized that there is heterogeneity in the study which is likely due to differences in study designs and background characteristics of the subjects, but according to the regression meta-analysis, we found that change in age, study type, a location of the study and indication for HSCT could potentially explain the heterogeneity.

We believed that there is still more to study regarding an association between TBI, HSCT and development of DM/IGM as DM is one of the most debilitating diseases with severe consequences if left untreated (White, 2015). Survivors might not realize that while they are being "cured" of one life-threatening condition; after the treatment, their risk of developing other chronic co-morbidity is not infinitesimal, they should be aware that they are at higher risk of developing DM/IGM and frequent monitoring is warranted (Wei et al., 2016). Our meta-analysis of clinical trials demonstrated that TBI significantly increased the risk of development of DM/IGM, but this is still an undiscovered field and further research is needed to clarify if the association truly stems directly from TBI or treatment with HSCT as a whole. We suggested that further large, prospective, controlled trials to investigate the long-term outcomes and treatment option for DM/IGM in the future as this is a rapidly expanding field of treatment potentials.
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